tim akhurst
机构: Peter MacCallum Cancer Centre
每年引用次数
引用次数
引用: 16,440
H-指数: 64
I10-指数 : 124
出版物: 287
SU‐DD‐A4‐01: The Estimation of the Uncertainty of Activity Concentrations in PET Images
C Schmidtlein , D Bailey , T Akhurst , W Wang
Medical Physics 36 ( 6) 2426 -2426
2009
Comparison of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography in the detection of recurrent colorectal carcinoma.
AM Scott , T Akhurst , SU Berlangieri , A Hannah
JOURNAL OF NUCLEAR MEDICINE 37 ( 5) 519 -519
2
1996
Validation of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) with surgical pathology in the detection of recurrent colorectal carcinoma.
T Akhurst , AM Scott , SU Berlangieri , A Hannah
JOURNAL OF NUCLEAR MEDICINE 37 ( 5) 515 -515
1996
An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer-Discussion
GL Walsh , RH Feins , E Vallieres , S Swanson
ANNALS OF THORACIC SURGERY 73 ( 1) 264 -265
2002
Single-centre experience of treating men with metastatic castration-resistant prostate cancer with Lutetium-177 PSMA-I&T using TheraP-like treatment algorithm
E Medhurst , R Alipour , T Akhurst , A Azad
INTERNAL MEDICINE JOURNAL 52 17 -18
2022
577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
SK Sandhu , AM Joshua , L Emmett , L Spain
Annals of Oncology 32 S626 -S627
19
2021
Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
MS Hofman , S Sandhu , P Eu , J Price
Annals of Oncology 28 v270 -v270
11
2017
HIGH EFFICACY FROM A PERSONALISED APPROACH USING Y-90-DOTA-OCTREOTATE SEQUENCED WITH (LU)-L-177-DOTA-OCTREOTATE INDUCTION PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT) FOR BULKY NEUROENDOCRINE TUMOURS
G Kong , J Callahan , M Hofman , D Pattison
Internal Medicine Journal 46 25 -25
1
2016
Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)
G Kong , J Callahan , M Hofman , D Pattison
Neuroendocrinology 103 93 -93
1
2016
PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma
DA Pattison , G Kong , MS Hofman , T Akhurst
Journal of Neuroendocrinology 35 203 -203
2023
IMPROVED SURVIVAL OF POOR PROGNOSIS FDG-AVID NEUROENDOCRINE TUMOURS WITH LU-177 OCTREOTATE PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT)
MS Hofman , R Kashyap , G Kong , T Akhurst
Internal Medicine Journal 45 13 -13
2015
PERSONALISED'TIME-PER-FRAME'FOR WHOLE BODY (68) GA-DOTATATE PET/CT SCANNING
E Hong , D Binns , J Callahan , T Akhurst
INTERNAL MEDICINE JOURNAL 44 17 -17
2014
PRACTICAL AND TECHNICAL CONSIDERATIONS OF PET IMAGING FOLLOWING THERAPEUTIC DOSES OF Y-90-OCTREOTATE. IS IT FEASIBLE?
D Binns , T Akhurst , MS Hofman , P Jackson
INTERNAL MEDICINE JOURNAL 42 33 -33
2012
DOSIMETRY OF I-124-PEG-AVP0458 DIABODY IN PATIENTS WITH TAG-72 POSITIVE OVARIAN OR PROSTATE CANCER
SJ Gong , GJ O'Keefe , ST Lee , T Akhurst
INTERNAL MEDICINE JOURNAL 45 40 -41
2015
Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxylglucose: Comparison of filtered back projection and iterative reconstruction with segmented attenuation correction
A Turlakow , SM Larson , F Coakley , T Akhurst
The Quarterly Journal of Nuclear Medicine and Molecular Imaging 45 ( 3) 235 -235
25
2001
Decreased PET SUV after induction chemotherapy is associated with improved survival in malignant pleural mesothelioma (MPM)
RM Flores , T Akhurst , L Krug , M Gonen
Journal of Clinical Oncology 23 7066 -7066
3
2005
A prospective study of 18FDG-pet scanning in preoperative melanoma patients
MS Brady , T Akhurst , K Spanknebal , M Gonen
Journal of Clinical Oncology 22 7520 -7520
1
2004
General Thoracic Surgery (GTS)-Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma
RM Flores , T Akhurst , M Gonen , SM Larson
Journal of Thoracic and Cardiovascular Surgery 126 ( 1) 11 -16
2003
F-18-FDG PET in the evaluation of patients with gallbadder cancer
CU Corvera , T Akhurst , RP DeMatteo , M D'Angelica
Gastroenterology 126 ( 4) A786 -A786
1
2004
Recent femoral arterial catheterisation is associated with increased FDG uptake in the groin
T Akhurst , Y Fong , LA Brody , G Getrajdman
EUROPEAN JOURNAL OF NUCLEAR MEDICINE 28 ( 8) 1079 -1079
2001